Simulations Plus sells software that helps drug makers test ideas on a computer, but many of its customers are cutting back or merging, which can slow new deals and renewals. At the same time, new AI features could keep the products relevant, yet cheaper tools and tougher pricing pressure may make it harder to protect profits.Read more
Key Takeaways The company anticipates notable earnings growth driven by increased revenue from QSP models and cross-selling post-acquisition units. A disciplined growth strategy aiming for higher EBITDA margins supports potential profitability amidst challenging macroeconomic conditions.Read more
Key Takeaways Advanced AI integration and a unified operating model are set to boost innovation, accelerate software adoption, and drive sustained operational efficiencies. Expansion into new clinical trial and R&D verticals positions the company to capture larger, recurring revenue streams and long-term margin expansion globally.Read more
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
